MedTrace Logo

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia

NCT00100971 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2013-01-04

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with acute myeloid leukemia.

Conditions

Interventions

DRUG

autologous tumor cell vaccine

DRUG

therapeutic autologous dendritic cells

PROCEDURE

tumor cell-derivative vaccine therapy

Sponsors & Collaborators

  • Boston Medical Center

    lead OTHER

Principal Investigators

  • Adam Lerner, MD · Boston Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100971 on ClinicalTrials.gov